Inclisiran in patients with acute ischemic stroke: first data

Aim. To evaluate the effect of inclisiran therapy on parameters of lipid metabolism in hospitalized patients with acute ischemic stroke.

Material and methods. A prospective, observational, non-randomized study was performed. The study included 12 patients with acute ischemic stroke prescribed with a combination lipid-lowering therapy with inclisiran (284 mg as a single dose). At 15 days after the start of therapy, changes in blood lipid composition were assessed. For quantitative variables, median, maximum and minimum values were determined. The significance of differences between related samples in quantitative variables was assessed using the Mann-Whitney test.

Results. Before the start of combination lipid-lowering therapy, total cholesterol (TC) was 7.33 mmol/l and low-density lipoprotein C (LDL-C) was 5.23 mmol/l. At 15 days after the start of inclisiran therapy, TC significantly decreased by 52.1 % and LDL-C decreased by 71.1 %. The proportion of patients who reached the LDL-C goal was 66.7 %. There were no adverse events considered by the investigators to be related with the therapy.

Conclusion. The strategy of early administration of inclisiran (or its combination with a statin) in patients with ischemic stroke allows safe achievement of a significant reduction in LDL-C already in 15 days after the start of therapy.

1. Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):98–103. DOI: 10.17116/jnevro201811808198

2. Quinn KL, Lam GY, Walsh JF, Bhéreur A, Brown AD, Chow CW et al. Cardiovascular Considerations in the Management of People With Suspected Long COVID. Canadian Journal of Cardiology. 2023;39(6):741–53. DOI: 10.1016/j.cjca.2023.04.003

3. Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and Cardiovascular Disease: What We Know in 2021. Current Atherosclerosis Reports. 2021;23(7):37. DOI: 10.1007/s11883-021-00935-2

4. Federal State Statistics Service. Health in Russia. 2019. Statistical book. -M.: Rosstat;2019. - 170p. https://www.gks.ru/storage/mediabank/Zdravoohran-2019.pdf]. ISBN 978-5-89476-470-2

5. Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D et al. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):439–58. DOI: 10.1016/S1474-4422(19)30034-1

6. Gattringer T, Posekany A, Niederkorn K, Knoflach M, Poltrum B, Mutzenbach S et al. Predicting Early Mortality of Acute Ischemic Stroke: Score-Based Approach. Stroke. 2019;50(2):349–56. DOI: 10.1161/STROKEAHA.118.022863

7. Boulanger M, Béjot Y, Rothwell PM, Touzé E. Long‐Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2018;7(2):e007267. DOI: 10.1161/JAHA.117.007267

8. Mohan KM, Wolfe CDA, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489–94. DOI: 10.1161/STROKEAHA.110.602615

9. Skajaa N, Adelborg K, Horváth-Puhó E, Rothman KJ, Henderson VW, Thygesen LC et al. Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark: A Nationwide Registry Study. Neurology. 2021; [Online ahead of print]. DOI: 10.1212/WNL.0000000000013118

10. Boytsov S.A., Drapkina O.M., Shlyakhto E.V., Konradi A.O., Balanova Yu.A., Zhernakova Yu.V. et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):143– 52. DOI: 10.15829/1728-8800-2021-3007

11. Boehme AK, Esenwa C, Elkind MSV. Stroke Risk Factors, Genetics, and Prevention. Circulation Research. 2017;120(3):472–95. DOI: 10.1161/CIRCRESAHA.116.308398

12. Paraskevas KI, Veith FJ, Eckstein H-H, Ricco J-B, Mikhailidis DP. Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. Annals of Translational Medicine. 2020;8(19):1265. DOI: 10.21037/atm.2020.02.176

13. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–467. DOI: 10.1161/STR.0000000000000375

14. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA cardiology. 2018;3(9):823–8. DOI: 10.1001/jamacardio.2018.2258

15. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250– 97. DOI: 10.15829/1560-4071-2023-5471

16. Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal. 2022;43(8):830–3. DOI: 10.1093/eurheartj/ehab718

17. Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovascular Research. 2020;116(11):e136–9. DOI: 10.1093/cvr/cvaa212

18. Ischemic stroke and transient ischemic attack in adults. Clinical recommendations. 2022. Av. at: https://evidence-neurology.ru/content/downloadfiles/13/kr-po-ii-i-tia_2022_finalnii-v_ru_1650370148.pdf. https://evidence-neurology.ru/content/downloadfiles/13/kr-po-ii-i-tia_2022_finalnii-v_ ru_1650370148.pdf]

19. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020;382(16):1507–19. DOI: 10.1056/NEJMoa1912387

20. Boytsov S.A., Piradov M.A., Tanashyan M.M., Voznyuk I.A., Yezhov M.V., Oshchepkova E.V. et al. Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):7–10. DOI: 10.17116/jnevro20221220517

21. Ay H, Benner T, Murat Arsava E, Furie KL, Singhal AB, Jensen MB et al. A Computerized Algorithm for Etiologic Classification of Ischemic Stroke: The Causative Classification of Stroke System. Stroke. 2007;38(11):2979–84. DOI: 10.1161/STROKEAHA.107.490896

22. Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S et al. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of Clinical Lipidology. 2023;17(3):392–400. DOI: 10.1016/j.jacl.2023.04.010

23. Medvedeva E.A., Grigorenko E.A., Mitkovskaya N.P. Innovative lipidlowering therapy: experience of inclisiran use in the Republic of Belarus. Russian Journal of Cardiology. 2023;28(4):53–61. DOI: 10.15829/1560-4071-2023-5417

24. Ueberdiek L, Jehn U, Pavenstädt H, Gebauer K, Reuter S. Novel Therapeutic Strategies for Dyslipidemia: First Report of Inclisiran Therapy in a Kidney Transplanted Patient. Transplant International. 2023;36:11104. DOI: 10.3389/ti.2023.11104

25. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine. 2017;376(15):1430–40. DOI: 10.1056/NEJMoa1615758

26. Shafqat S, Arif H, Aijaz B, Islam M, Aftab U, Kumar S. Drug compliance after stroke and myocardial infarction: A comparative study. Neurology India. 2007;55(2):130–5. DOI: 10.4103/0028-3886.32783

27. Rajahthurai SD, Farrukh MJ, Makmor-Bakry M, Tan HJ, Fatokun O, Mohd Saffian S et al. Use of Complementary and Alternative Medicine and Adherence to Medication Therapy Among Stroke Patients: A Meta-analysis and Systematic Review. Frontiers in Pharmacology. 2022;13:870641. DOI: 10.3389/fphar.2022.870641

28. Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. The Journal of Headache and Pain. 2022;23(1):54. DOI: 10.1186/s10194-022-01413-z

29. Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurology. 2019;76(5):526–35. DOI: 10.1001/jamaneurol.2019.0079

30. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016;374(14):1321–31. DOI: 10.1056/NEJMoa1506930

31. Yang Y, Shi Y-Z, Zhang N, Wang S, Ungvari GS, Ng CH et al. The Disability Rate of 5-Year Post-Stroke and Its Correlation Factors: A National Survey in China. PLOS ONE. 2016;11(11):e0165341. DOI: 10.1371/journal.pone.0165341

32. Banda KJ, Chu H, Kang XL, Liu D, Pien L-C, Jen H-J et al. Prevalence of dysphagia and risk of pneumonia and mortality in acute stroke patients: a meta-analysis. BMC Geriatrics. 2022;22(1):420. DOI: 10.1186/s12877-022-02960-5

33. Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses. European Stroke Journal. 2016;1(2):65–75. DOI: 10.1177/2396987316647187

34. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G et al. EUWide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology. 2021;28(11):1279–89. DOI: 10.1093/eurjpc/zwaa047

35. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455

36. Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. The Lancet Regional Health - Europe. 2023;29:100624. DOI: 10.1016/j.lanepe.2023.100624

37. Yanishevskiy S.N., Skiba Ya.B., Polushin A.Yu. Statins in patients with acute ischemic stroke: when we should start therapy? Arterial Hypertension. 2021;27(1):16–28. DOI: 10.18705/1607-419X-2021-27-1-16-28

38. Catapano AL, De Caterina R, Jukema JW, Klempfner R, Landmesser U, Schiele F et al. Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative. Clinical Cardiology. 2023;46(4):407–15. DOI: 10.1002/clc.23988

39. Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clinical Cardiology. 2019;42(3):391–9. DOI: 10.1002/clc.23160

40. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423. DOI: 10.1136/bmj.326.7404.1423

41. Ostwald DA, Schmitt M, Peristeris P, Gerritzen T, Durand A. The Societal Impact of Inclisiran in England: Evidence From a Population Health Approach. Value in Health. 2023;26(9):1353–62. DOI: 10.1016/j.jval.2023.05.002

42. What’s new in clinical guideline Ministry of Health RF ‘Disorders of lipid metabolism 2023’. Av. at: https://scardio.ru/content/activities/2023/11042023.pdf.

43. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713– 22. DOI: 10.1056/NEJMoa1615664

44. Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. The American Journal of Cardiology. 2016;117(1):40–7. DOI: 10.1016/j.amjcard.2015.10.021

45. Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P et al. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016;134(24):1931–43. DOI: 10.1161/CIRCULATIONAHA.116.024604

46. Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. The Lancet Diabetes & Endocrinology. 2023;11(2):109–19. DOI: 10.1016/S2213-8587(22)00353-9

47. Koenig W, Ray KK, Landmesser U, Leiter LA, Schwartz GG, Wright RS et al. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. American Journal of Preventive Cardiology. 2023;14:100503. DOI: 10.1016/j.ajpc.2023.100503

48. Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, LowDensity Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals. 2023;16(4):577. DOI: 10.3390/ph16040577

49. Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. Stroke. 2019;50(12):3532–9. DOI: 10.1161/ STROKEAHA.119.026872

50. Nambi V, Agha A. Inclisiran: A Game Changer in a Changing Game? Journal of the American College of Cardiology. 2021;77(9):1194–6. DOI: 10.1016/j. jacc.2021.01.008

51. Tanashyan M.M., Shamalov N.A., Voznyuk I.A., Yanishevsky S.N., Vinogradov O.I., Khasanova D.R. et al. Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion). Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):108–13. DOI: 10.14412/2074-2711-2022-4-108-113